Iniciar sesión Regístrese gratis

Edesa Biotech Quick ratio

¿Qué es el Quick ratio de Edesa Biotech?

El Quick ratio de Edesa Biotech, Inc. es 1.29

¿Cuál es la definición de Quick ratio?



El ratio rápido es la relación de liquidez que mide la capacidad de una empresa para usar sus activos rápidos para cumplir con sus obligaciones a corto plazo de forma inmediata.

The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.

Quick ratio de compañías en Sector Health Care en NASDAQ en comparadas con Edesa Biotech

¿Qué hace Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Empresas con quick ratio similar a Edesa Biotech